Abstract | BACKGROUND:
Breast cancer stem cells with a CD44(+)CD24(-) phenotype are the origin of breast tumors. Strong CD44 expression in this population indicates its important role in maintaining the stem cell phenotype. Previous studies show that CD44 down-regulation causes CD44(+)CD24(-) breast cancer stem cells to differentiate into non-stem cells that are sensitive to antitumor drugs and lose many characteristics of the original cells. In this study, we determined tumor suppression in non-obese severe combined immunodeficiency mice using CD44 shRNA therapy combined with doxorubicin treatment. METHODS:
Tumor-bearing non-obese severe combined immunodeficiency mice were established by injection of CD44(+)CD24(-) cells. To track CD44(+)CD24(-) cells, green fluorescence protein was stably transduced using a lentiviral vector prior to injection into mice. The amount of CD44 shRNA lentiviral vector used for transduction was based on CD44 down-regulation by in vitro CD44 shRNA transduction. Mice were treated with direct injection of CD44 shRNA lentiviral vector into tumors followed by doxorubicin administration after 48 hours. The effect was evaluated by changes in the size and weight of tumors compared with that of the control. RESULTS: The combination of CD44 down-regulation and doxorubicin strongly suppressed tumor growth with significant differences in tumor sizes and weights compared with that of CD44 down-regulation or doxorubicin treatment alone. In the combination of CD44 down-regulation and doxorubicin group, the tumor weight was significantly decreased by 4.38-fold compared with that of the control group. CONCLUSION:
|
Authors | Phuc Van Pham, Ngoc Bich Vu, Thuy Thanh Duong, Tam Thanh Nguyen, Nhung Hai Truong, Nhan Lu Chinh Phan, Tue Gia Vuong, Viet Quoc Pham, Hoang Minh Nguyen, Kha The Nguyen, Nhung Thi Nguyen, Khue Gia Nguyen, Lam Tan Khat, Dong Van Le, Kiet Dinh Truong, Ngoc Kim Phan |
Journal | OncoTargets and therapy
(Onco Targets Ther)
Vol. 5
Pg. 77-84
( 2012)
ISSN: 1178-6930 [Electronic] New Zealand |
PMID | 22649280
(Publication Type: Journal Article)
|